Chun-Ze Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chun-Ze Zhou has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Liang Yin
Department of Interventional Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China
3 shared publicationsWei-Fu Lv
Department of Interventional Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China
3 shared publicationsYi-Jiang Zhu
Department of Interventional Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China
3 shared publications- De-Lei Cheng
Department of Interventional Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei City, China
2 shared publications Delei Cheng
Department of Interventional Radiology, The First Affiliated Hospital, University of Science and Technology of China
2 shared publicationsHan Cao
The Second Affiliated Hospital of Anhui Medical University, Hefei, China
2 shared publications
Latest Publications
- Open Access
- 11 October 2026
- Published by Springer Nature in BMC Gastroenterology
Preprocedural estimated glomerular filtration rate and all-cause mortality after TIPS in cirrhosis: a single-center retrospective cohort study
- 11 October 2026
- Published by Springer Nature in BMC Gastroenterology
Open AccessPreprocedural estimated glomerular filtration rate and all-cause mortality after TIPS in cirrhosis: a single-center retrospective cohort study
- Open Access
- 13 April 2026
- Published by Taylor & Francis in Renal Failure
- Vol. 48 (1) , 2650577
Incidence, associated factors and prognostic association of acute kidney injury after TIPS: a multicenter retrospective study
Transjugular intrahepatic portosystemic shunt (TIPS) is a minimally invasive, well-established procedure for managing complications of cirrhotic portal hypertension, such as variceal bleeding and r...
- 13 April 2026
- Published by Taylor & Francis in Renal Failure
- Vol. 48 (1) , 2650577
Open AccessIncidence, associated factors and prognostic association of acute kidney injury after TIPS: a multicenter retrospective study
Transjugular intrahepatic portosystemic shunt (TIPS) is a minimally invasive, well-established procedure for managing complications of cirrhotic portal hypertension, such as variceal bleeding and r...
- Open Access
- 6 June 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2514082
Comparing efficacy of different scoring models to predict hepatic encephalopathy after TIPS in cirrhotic patients
Assessing hepatic encephalopathy (HE) risk post-transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients is crucial. This study compares the predictive performance of Child-Pugh and Model for End-Stage Liver Disease (MELD), CLIFC-AD and Freiburg index of post-TIPS survival (FIPS) scores for overt and severe HE. To compare the predictive value of Child-Pugh, MELD, CLIFC-AD and FIPS scores for overt and severe HE post-TIPS in cirrhotic patients. We retrospectively analysed data from 406 cirrhotic TIPS patients (January 2017–January 2021). Scoring models were assessed for differentiation (C-index), calibration, clinical utility and overall performance at 1, 3, 6 and 12 months post-TIPS. Predictive performance for overt HE post-TIPS was low across models. FIPS had superior predictive ability for severe HE at 1 and 12 months post-TIPS (C-index: 0.781, 0.705). FIPS and CLIFC-AD showed good predictive capacity for severe HE in sarcopenic patients at 1 and 12 months (FIPS: C-index 0.863, 0.757; CLIFC-AD: C-index 0.748, 0.732). FIPS had the highest hazard ratio for severe HE (HR = 3.520, 95% CI: 2.134–5.807) and CLIFC-AD for overt HE (HR = 2.132, 95% CI: 1.581–2.874). FIPS and CLIFC-AD scores demonstrate significant predictive ability for severe HE post-TIPS, particularly in sarcopenic patients.
- 6 June 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2514082
Open AccessComparing efficacy of different scoring models to predict hepatic encephalopathy after TIPS in cirrhotic patients
Assessing hepatic encephalopathy (HE) risk post-transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients is crucial. This study compares the predictive performance of Child-Pugh and Model for End-Stage Liver Disease (MELD), CLIFC-AD and Freiburg index of post-TIPS survival (FIPS) scores for overt and severe HE. To compare the predictive value of Child-Pugh, MELD, CLIFC-AD and FIPS scores for overt and severe HE post-TIPS in cirrhotic patients. We retrospectively analysed data from 406 cirrhotic TIPS patients (January 2017–January 2021). Scoring models were assessed for differentiation (C-index), calibration, clinical utility and overall performance at 1, 3, 6 and 12 months post-TIPS. Predictive performance for overt HE post-TIPS was low across models. FIPS had superior predictive ability for severe HE at 1 and 12 months post-TIPS (C-index: 0.781, 0.705). FIPS and CLIFC-AD showed good predictive capacity for severe HE in sarcopenic patients at 1 and 12 months (FIPS: C-index 0.863, 0.757; CLIFC-AD: C-index 0.748, 0.732). FIPS had the highest hazard ratio for severe HE (HR = 3.520, 95% CI: 2.134–5.807) and CLIFC-AD for overt HE (HR = 2.132, 95% CI: 1.581–2.874). FIPS and CLIFC-AD scores demonstrate significant predictive ability for severe HE post-TIPS, particularly in sarcopenic patients.
- 22 January 2025
- Published by Elsevier in Journal of Biomechanics
- Vol. 181, 112516
Hemodynamic investigations on the portal hypertension and treatment of transjugular intrahepatic portosystemic shunt (TIPS) based on CFD simulation
- 22 January 2025
- Published by Elsevier in Journal of Biomechanics
- Vol. 181, 112516
Hemodynamic investigations on the portal hypertension and treatment of transjugular intrahepatic portosystemic shunt (TIPS) based on CFD simulation
- Open Access
- 9 April 2024
- Published by Springer Nature in Hepatology International
- Vol. 18 (4) , 1227-1237
Efficacy and safety of precision-guided transjugular extrahepatic portosystemic shunt (TEPS) in the management of cavernous transformation of the portal vein with portal hypertension: a case series
Background and aims: Performing a Transjugular intrahepatic portal system shunt (TIPS) in patients with portal vein cavernous transformation (CTPV) poses significant challenges. As an alternative, transjugular extrahepatic portal vein shunt (TEPS) may offer a potential solution for these patients. Nonetheless, the effectiveness and safety of TEPS remain uncertain. This case series study aimed to evaluate the efficacy and safety of TEPS in treating patients with CTPV portal hypertension complications. Methods: The study encompassed a cohort of 22 patients diagnosed with CTPV who underwent TEPS procedures. Of these, 13 patients manifested recurrent hemorrhagic episodes subsequent to conventional therapies, 8 patients grappled with recurrent or refractory ascites, and 1 patient experienced acute bleeding but refused endoscopic treatment. Comprehensive postoperative monitoring was conducted for all patients to rigorously evaluate both the technical and clinical efficacy of the intervention, as well as long-term outcomes. Results: The overall procedural success rate among the 22 patients was 95.5% (21/22).During the TEPS procedure, nine patients were guided by percutaneous splenic access, three patients were guided by percutaneous hepatic access, five patients were guided by transmesenteric vein access from the abdomen, and two patients were guided by catheter marking from the hepatic artery. Additionally, guidance for three patients was facilitated by pre-existing TIPS stents. The postoperative portal pressure gradient following TEPS demonstrated a statistically significant decrease compared to preoperative values (24.95 ± 3.19 mmHg vs. 11.48 ± 1.74 mmHg, p < 0.01).Although three patients encountered perioperative complications, their conditions ameliorated following symptomatic treatment, and no procedure-related fatalities occurred. During a median follow-up period of 14 months, spanning a range of 5 to 39 months, we observed four fatalities. Specifically, one death was attributed to hepatocellular carcinoma, while the remaining three were ascribed to chronic liver failure. During the follow-up period, no instances of shunt dysfunction were observed. Conclusions: Precision-guided TEPS appears to be a safe and efficacious intervention for the management of CTPV.
- 9 April 2024
- Published by Springer Nature in Hepatology International
- Vol. 18 (4) , 1227-1237
Open AccessEfficacy and safety of precision-guided transjugular extrahepatic portosystemic shunt (TEPS) in the management of cavernous transformation of the portal vein with portal hypertension: a case series
Background and aims: Performing a Transjugular intrahepatic portal system shunt (TIPS) in patients with portal vein cavernous transformation (CTPV) poses significant challenges. As an alternative, transjugular extrahepatic portal vein shunt (TEPS) may offer a potential solution for these patients. Nonetheless, the effectiveness and safety of TEPS remain uncertain. This case series study aimed to evaluate the efficacy and safety of TEPS in treating patients with CTPV portal hypertension complications. Methods: The study encompassed a cohort of 22 patients diagnosed with CTPV who underwent TEPS procedures. Of these, 13 patients manifested recurrent hemorrhagic episodes subsequent to conventional therapies, 8 patients grappled with recurrent or refractory ascites, and 1 patient experienced acute bleeding but refused endoscopic treatment. Comprehensive postoperative monitoring was conducted for all patients to rigorously evaluate both the technical and clinical efficacy of the intervention, as well as long-term outcomes. Results: The overall procedural success rate among the 22 patients was 95.5% (21/22).During the TEPS procedure, nine patients were guided by percutaneous splenic access, three patients were guided by percutaneous hepatic access, five patients were guided by transmesenteric vein access from the abdomen, and two patients were guided by catheter marking from the hepatic artery. Additionally, guidance for three patients was facilitated by pre-existing TIPS stents. The postoperative portal pressure gradient following TEPS demonstrated a statistically significant decrease compared to preoperative values (24.95 ± 3.19 mmHg vs. 11.48 ± 1.74 mmHg, p < 0.01).Although three patients encountered perioperative complications, their conditions ameliorated following symptomatic treatment, and no procedure-related fatalities occurred. During a median follow-up period of 14 months, spanning a range of 5 to 39 months, we observed four fatalities. Specifically, one death was attributed to hepatocellular carcinoma, while the remaining three were ascribed to chronic liver failure. During the follow-up period, no instances of shunt dysfunction were observed. Conclusions: Precision-guided TEPS appears to be a safe and efficacious intervention for the management of CTPV.
- Open Access
- 8 November 2023
- Published by Springer Nature in Research Square
Efficacy and Safety of Precision-Guided Transjugular Extrahepatic Portosystemic Shunt (TEPS) in the Management of Cavernous Transformation of the Portal Vein with Portal Hypertension: A Case Series
Background and Aims: Performing a Transjugular intrahepatic portal system shunt (TIPS) in patients with portal vein cavernous transformation (CTPV) poses significant challenges. As an alternative, transjugular extrahepatic portal vein shunt (TEPS) may offer a potential solution for these patients. Nonetheless, the effectiveness and safety of TEPS remain uncertain. This case series study aimed to evaluate the efficacy and safety of TEPS in treating patients with CTPV portal hypertension complications. Methods:The study encompassed a cohort of twenty-two patients diagnosed with CTPV who underwent TEPS procedures.Of these, thirteen patients manifested recurrent hemorrhagic episodes subsequent to conventional therapies, eight patients grappled with recurrent or refractory ascites, and one patient experienced acute bleeding but refused endoscopic treatment. Comprehensive postoperative monitoring was conducted for all patients to rigorously evaluate both the technical and clinical efficacy of the intervention,as well as long-term outcomes. Results:The overall procedural success rate among the 22 patients was 95.5% (21/22).During the TEPS procedure, nine patients were guided by percutaneous splenic access, three patients were guided by percutaneous hepatic access, five patients were guided by transmesenteric vein access from the abdomen, and two patients were guided by catheter marking from the hepatic artery. Additionally, guidance for three patients was facilitated by pre-existing TIPS stents.The postoperative portal pressure gradient following TEPS demonstrated a statistically significant decrease compared to preoperative values (24.95±3.19 mmHg vs. 11.48±1.74 mmHg, P<0.01).Although three patients encountered perioperative complications, their conditions ameliorated following symptomatic treatment, and no procedure-related fatalities occurredDuring a median follow-up period of 14 months, spanning a range of 5 to 39 months, we observed four fatalities. Specifically, one death was attributed to hepatocellular carcinoma, while the remaining three were ascribed to chronic liver failure.During the follow-up period, no instances of shunt dysfunction were observed. Conclusions:Precision-guided TEPS appears to be a safe and efficacious intervention for the management of CTPV.
- 8 November 2023
- Published by Springer Nature in Research Square
Open AccessEfficacy and Safety of Precision-Guided Transjugular Extrahepatic Portosystemic Shunt (TEPS) in the Management of Cavernous Transformation of the Portal Vein with Portal Hypertension: A Case Series
Background and Aims: Performing a Transjugular intrahepatic portal system shunt (TIPS) in patients with portal vein cavernous transformation (CTPV) poses significant challenges. As an alternative, transjugular extrahepatic portal vein shunt (TEPS) may offer a potential solution for these patients. Nonetheless, the effectiveness and safety of TEPS remain uncertain. This case series study aimed to evaluate the efficacy and safety of TEPS in treating patients with CTPV portal hypertension complications. Methods:The study encompassed a cohort of twenty-two patients diagnosed with CTPV who underwent TEPS procedures.Of these, thirteen patients manifested recurrent hemorrhagic episodes subsequent to conventional therapies, eight patients grappled with recurrent or refractory ascites, and one patient experienced acute bleeding but refused endoscopic treatment. Comprehensive postoperative monitoring was conducted for all patients to rigorously evaluate both the technical and clinical efficacy of the intervention,as well as long-term outcomes. Results:The overall procedural success rate among the 22 patients was 95.5% (21/22).During the TEPS procedure, nine patients were guided by percutaneous splenic access, three patients were guided by percutaneous hepatic access, five patients were guided by transmesenteric vein access from the abdomen, and two patients were guided by catheter marking from the hepatic artery. Additionally, guidance for three patients was facilitated by pre-existing TIPS stents.The postoperative portal pressure gradient following TEPS demonstrated a statistically significant decrease compared to preoperative values (24.95±3.19 mmHg vs. 11.48±1.74 mmHg, P<0.01).Although three patients encountered perioperative complications, their conditions ameliorated following symptomatic treatment, and no procedure-related fatalities occurredDuring a median follow-up period of 14 months, spanning a range of 5 to 39 months, we observed four fatalities. Specifically, one death was attributed to hepatocellular carcinoma, while the remaining three were ascribed to chronic liver failure.During the follow-up period, no instances of shunt dysfunction were observed. Conclusions:Precision-guided TEPS appears to be a safe and efficacious intervention for the management of CTPV.
- 6 January 2023
- Published by Elsevier in Acta Biomaterialia
- Vol. 158, 649-659
Gold nanobipyramid@copper sulfide nanotheranostics for image-guided NIR-II photo/chemodynamic cancer therapy with enhanced immune response
- 6 January 2023
- Published by Elsevier in Acta Biomaterialia
- Vol. 158, 649-659
Gold nanobipyramid@copper sulfide nanotheranostics for image-guided NIR-II photo/chemodynamic cancer therapy with enhanced immune response